

Stahl's Illustrated

Index

- acetylcholine 21
- actigraphy 46
- adenosine 98
- advanced sleep phase disorder (ASPD) 68
- agomelatine 80
- amphetamine 93
- anticonvulsants 90
- antidepressants
 - hypersomnia treatment 94
 - insomnia treatment 87
- antihistamines 51
- antipsychotics 90
- Apnea-Hypopnea Index (AHI) 72
- armodafinil 92, 95, 96
- arousal spectrum 4
- assessment tools 43
 - actigraphy 46
 - Epworth Sleepiness Scale 48
 - Morningness-Eveningness Questionnaire 50
 - Multiple Sleep Latency Test 45
 - Pittsburgh Sleep Quality Index 49
 - polysomnography 44
 - sleep/wake diary 47
- atomoxetine 93
- autoimmunity in disorders of hypersomnolence 41

- basal forebrain (BF) 11, 17, 24
- behavioral responses, goal-directed 25
- benzodiazepine hypnotics 51
 - insomnia treatment 84, 85
 - RLS treatment 101

- bipolar disorder, clock genes linked to 34
- brain regions involved in sleep/wake cycle 10
- bright light therapy 81

- caffeine 98
- Cambridge-Hopkins Diagnostic Questionnaire for RLS (CH-RLSq) 75
- cancer risk and circadian rhythms 32, 36, 37
- cataplexy, narcolepsy with 64
 - pharmacological treatments 92, 94, 97
- cell division and circadian rhythms 36
- central and peripheral clocks, misalignment
 - between 32
- circadian rhythms 7
 - bright light therapy 81
 - cancer and 37
 - cell division 36
 - disorders 66–70
 - resetting 78
 - zeitgebers 7
 - light 8
 - melatonin 27, 80, 81
- circadian wake drive 5
- clarithromycin, wakefulness promotion 99
- cognitive behavioral therapy 83
- cognitive functioning and sleep 35
- CREB, photic activation of 31

- delayed sleep phase disorder (DSPD) 69
- depression
 - clock genes associated with 34
 - insomnia link 55

- diagnosis
 - hypersomnia 65
 - insomnia 56–57
- diary keeping 47
- dopamine (DA)
 - agonists, RLS treatment 101
 - caffeine reducing affinity of D2 receptors 98
 - deficiency in, link to RLS 73, 74
 - hypocretin/orexin causing release of 15
 - increased by modafinil 96
 - levels during sleep/wake cycle 22
 - regulation by molecular clock 33
- doxepin 87
- duration of sleep 3
- economic costs of disorders 2
- electrocardiogram (ECG) 44
- electroencephalogram (EEG) 6, 44, 75
- electromyogram (EMG) 44
- electrooculogram (EOG) 44
- epidemiology 2
- Epworth Sleepiness Scale (ESS) 48, 57
- excessive daytime sleepiness 59, 61–62
 - during work shift 67
 - narcolepsy 63–64
 - pharmacological treatments 92, 93, 94, 97
- excessive nighttime arousal *see* insomnia
- GABA 9, 11, 24
 - caffeine 98
 - insomnia 54
 - levels throughout sleep/wake cycle 19
 - psychotropic agents 51
 - RLS treatment 101
 - sodium oxybate 97
- galanin 5, 11, 18, 19
- gamma-hydroxybutyrate (GHB) 97
- gastrin releasing peptide (GRP) 9
- glutamate 23, 24, 26, 30, 88
- H1N1 influenza infection and narcolepsy risk 41
- histamine 12, 13, 24
 - and antidepressants 87
 - H3 receptor antagonists 99
 - increased by modafinil 96
 - levels throughout sleep/wake cycle 22
 - receptors regulating 26
- homeostatic sleep drive 5
- hypersomnia 60
 - autoimmunity 41
 - differential diagnosis 65
 - emerging treatments 99
 - idiopathic 61
 - narcolepsy 63–64
 - pharmacological treatments 92–98
 - recurrent 62
- hypoarousal during the day *see* excessive daytime sleepiness
- hypocretin/orexin (Hcrt/Ox) 23
 - agonists, hypersomnia treatment 99
 - antagonists 89
 - hypothetical actions of 88
 - levels and hypersomnia diagnosis 65
 - levels during sleep/wake cycle 20
 - and motivated behaviors 25
 - narcolepsy with cataplexy 64
 - autoimmunity 41
 - projections 24
 - role in sleep circuit 18
 - role in wake circuit 13–17
- hypothalamus 9, 24, 89
- idiopathic hypersomnia 61
- immunity
 - autoimmunity in hypersomnolence 41
 - and sleep/wake cycle 40
- immunomodulation, hypersomnia treatment 99
- insomnia 52
 - autonomic nervous system abnormalities 54
 - conditions associated with 53
 - DSM-5 diagnostic criteria 56
 - genetic factors 54
 - neuroanatomical abnormalities 54
 - neurobiological abnormalities 54
 - nonpharmacological treatments 83
 - pharmacological treatments 84–90
 - and psychiatric illness 55
 - serotonin receptors 58
 - suggested criteria for defining 57
- Insomnia Severity Index (ISI) 58

- intensive sleep retraining 83
- iron deficiency and RLS 74, 101
- Kleine-Levin Syndrome 62
- lateral hypothalamus (LH) 10, 11, 13, 18, 64, 99
- light 8
 - bright light therapy 81
 - control of molecular clock 30–31
- locus coeruleus (LC) 10, 16, 18, 23, 64
- Maintenance of Wakefulness Test 45
- melatonin 8, 27
 - light therapy 81
 - receptor agonists 80
 - reduced nocturnal secretion 54
- methylphenidate 83
- misalignment between central and peripheral clocks 32
- modafinil/armodafinil 95–96
- molecular clock 7
 - clock genes associated with psychiatric disorders 34
 - light control of 30–31
 - misalignment between central and peripheral clocks 32
 - neurotransmitter regulation 33
 - and nutrition 39
 - transcription factors 28–29
- monoamine oxidase inhibitors (MAOIs) 94
- Morningness-Eveningness Questionnaire (MEQ) 50
- motivated behaviors, hypocretin/orexin neuron excitement 25
- Multiple Sleep Latency Test (MSLT) 45, 61, 65, 72
- narcolepsy 63–64
- neurotransmitter levels throughout sleep/wake cycle 19–22
- neurotransmitter regulation by molecular clock 33
- Non-24-Hour Sleep-Wake disorder 70
- nonbenzodiazepine hypnotics 51, 84, 86
- nonpharmacological treatments
 - circadian rhythm disorders 78, 81
 - insomnia 83
 - sleep hygiene 79
- norepinephrine (NE) 64
 - modafinil increasing 96
 - sleep circuit 18
 - sleep/wake cycle 22
 - wake circuit 16
- nucleus accumbens (NAC) 24
- nutrition and the molecular clock 39
- obesity 38
- obstructive sleep apnea 71
 - diagnosis 72
 - treatment of 100
- orexin, modafinil increasing 96
- periodic limb movements (PLMs) 73
- peripheral and central clocks, misalignment between 32
- Pittsburgh Sleep Quality Index (PSQI) 49, 57
- polysomnography (PSG) 44, 45, 57, 61, 65, 72
- promotion of sleep 82
- promotion of wakefulness 91
- psychiatric disorders
 - clock genes associated with 34
 - insomnia link 53, 55
- psychotropic agents 51
- purpose of sleep 2
- ramelteon 80
- raphe nuclei (RN) 10, 11
 - serotonin release from 17, 18, 24, 64
- rapid eye movement (REM) sleep 6, 19–22
 - abnormal in narcolepsy 63
 - for cognitive functioning 35
 - measurement 44
 - psychotropics affecting 51
 - SOREMPs (sleep onset REMs) 61, 63, 65
- recurrent hypersomnia 62
- relaxation training 83
- Respiratory Disturbance Index (RDI) 72
- restless legs syndrome (RLS) 73
 - Cambridge Hopkins Diagnostic Questionnaire (CH-RLSq) 75

- restless legs syndrome (RLS) (cont.)
 - neurobiology of 74
 - treatment of 101
- retinohypothalamic tract 8, 9, 30, 70
- seasonal affective disorder (SAD) 34
- selective serotonin reuptake inhibitors (SSRIs) 51, 94
- selegiline 94
- serotonin antagonist and reuptake inhibitors (SARIs) 87
- serotonin levels during sleep/wake cycle 22
- serotonin-norepinephrine reuptake inhibitors (SNRIs) 94
- serotonin receptors and insomnia 58
- shift work disorder 67
- sleep circuit 11
 - triggering 18
- sleep cycle 6
- sleep hygiene 79
- sleep promotion 82
- sleep restriction therapy 83
- sleep/wake cycle 5–6
 - brain regions involved in 10
 - disturbances of, detrimental effects 2
 - neurotransmitter levels 19–22
- sleep/wake diary 47
- sodium oxybate 97
- SOREMPs (sleep onset REMs) 61, 63, 65
- stimulants 79, 91, 93, 98
- stimulus control therapy 83
- striatum 24, 88, 98
- subjective sleepiness 65
- substance abuse
 - cause of hypersomnia 60
 - insomnia as risk factor for 53, 55
- suprachiasmatic nucleus (SCN) 5, 8, 70
 - control of sleep 9
 - light control of molecular clock 30–31
 - misalignment with peripheral clocks 32
- suvorexant 89
- tasimelteon 70, 80
- thalamus 24, 64, 88
- thyrotropin-releasing hormone (TRH) agonists 99
- transcription factors 28–29
- trazodone 87
- treatment 77
 - circadian rhythm disorders 78–81
 - hypersomnia 91–99
 - insomnia 82–90
 - obstructive sleep apnea 100
- tricyclic antidepressants (TCAs) 51, 87, 92, 94
- tuberomammillary nucleus (TMN) 11, 23, 24, 99
- type 2 diabetes 38
- vasoactive intestinal peptide (VIP) 9
- ventral tegmental area (VTA) 10
 - dopamine release from 15, 24
 - sleep circuit 11
- ventrolateral preoptic area (VLPO) 10, 11, 64
- wake circuit 12–17
- wakefulness promotion 91
- Z-drugs 86
- zeitgebers 7–8